Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2023-12-06 00:00:00 ET · period of report 2023-12-04 · accession 0001209191-23-057640 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-06 | 2023-12-04 | OVID | LEVIN JEREMY M | CEO, Dir | G - Gift | $0.00 | -1.15M | 4.17M | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-04 | G | D | 573,275 | $0.00 | 3,598,467 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-04 | G | D | 573,275 | $0.00 | 4,171,742 | D | — | — | (F2) This direct ownership total corrects an inadvertent administrative error in the number of shares of common stock that were reported as directly held on the Form 4 filed by the reporting executive on September 1, 2020. Before the transactions reported herein, the reporting executive held 4,745,017 shares of common stock directly |